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The slow digestible disaccharide isomaltulose (iso; Palatinosee) is available as novel functional carbohydrate ingredient for manufacturing of
low glycaemic foods and beverages. Although basically characterised, various information on physiological effects of iso are still lacking.
Thus, the objective of the present study was to expand scientiﬁc knowledge of physiological characteristics of iso by a set of three human inter-
vention trials. Using an ileostomy model, iso was found to be essentially absorbed, irrespective of the nature of food (beverage and solid food).
Apparent digestibility of 50g iso from two different meals was 95·5 and 98·8%; apparent absorption was 93·6 and 96·1%, respectively. In healthy
volunteers, a single dose intake of iso resulted in lower postprandial blood glucose and insulin responses than did sucrose (suc), while showing
prolonged blood glucose delivery over 3h test. In a 4-week trial with hyperlipidaemic individuals, regular consumption of 50g/d iso within a
Western-type diet was well tolerated and did not affect blood lipids. Fasting blood glucose and insulin resistance were lower after the 4-week
iso intervention compared with baseline. This would be consistent with possible beneﬁcial metabolic effects as a consequence of the lower
and prolonged glycaemic response and lower insulinaemic burden. However, there was no signiﬁcant difference at 4 weeks after iso compared
with suc. In conclusion, the study shows that iso is completely available from the small intestine, irrespective of food matrix, leading to a
prolonged delivery of blood glucose. Regular iso consumption is well tolerated also in subjects with increased risk for vascular diseases.
Isomaltulose: Metabolic markers: Ileostoma: Hyperlipidaemia: Low glycaemic foods
There is growing interest in the glycaemic properties of foods
and the possible contribution of glycaemic properties to nutri-
tion and health
(1). Over the last decades, a growing body of
research has shown that diets based on low glycaemic and
low insulinaemic foods reduce the risk of developing diabetes,
obesity and CVD, improve blood glucose control in people
with diabetes, may inﬂuence blood lipids and can be useful
for weight management
(2–4). Furthermore, low glycaemic
and low insulinaemic foods are considered as favourable as
they could contribute to a prolonged feeling of satiety and a
sustained energy release with further implications for physical
and mental performance
(5,6).
Conventional carbohydrate ingredients for the manufactur-
ing of composite foods, like processed starch, glucose as
such, glucose syrups, maltodextrins but also sucrose (suc)
are predominantly more rapidly digested carbohydrates that
induce a relatively high glycaemic and insulinaemic response.
Even so, food manufacturers have the possibility to modify
the glycaemic impact of foods by substitution of these
more rapidly digested and thus high glycaemic carbohydrates
by low glycaemic carbohydrate alternatives. Isomaltulose
(iso; Palatinosee) is a recent example of such an alternative
carbohydrate ingredient.
Iso is a reducing disaccharide comprised of glucose and
fructose joined by an a-1,6-glycosidic bond. iso is naturally
present in honey and sugarcane juice
(7). Commercial iso
(Palatinosee) is manufactured from food-grade suc by
enzymatic rearrangement of the glycosidic linkage followed
by crystallisation
(8–10). Iso has been used as sugar in Japan
and other Asian countries for more than two decades. In the
European Union, it was approved as Novel Food in 2005
(11)
and is marketed as generally recognised as safe in the US
(12).
Taste and appearance of iso are similar to suc, and the
sweetness is about half of that of suc. In contrast to suc, iso
is hardly utilised by oral plaque bacteria and is thus non-
cariogenic
(13). Due to its more stable a-1,6-glycosidic bond
iso is slowly, though completely, hydrolysed by small intesti-
nal disaccharidases. In studies utilising human small intestinal
mucosa homogenates as enzyme source, iso was hydrolysed
with Vmax of 26–45% compared with suc
(7). The released
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nmonosaccharides glucose and fructose are absorbed and
metabolised. Due to the slower release and absorption of the
monosaccharides, blood glucose and insulin response after
oral administration were found to rise slower and reach
lower maxima than after suc administration. The glucose
supply is thus sustained over a longer period of time
(7).
With a calculated glycaemic index (GI) of 32, iso is a low
glycaemic carbohydrate
(14).
The digestibility characteristics of iso have been particu-
larly derived from earlier in vitro and animal studies. Up to
present, no human data were available whether iso, when
incorporated in complex food and beverages, is indeed a
slowly digestible, yet fully available carbohydrate. The studies
carried out with iso so far are mainly single-meal trials in
healthy human subjects. Thus, health effects of regular and
longer-term consumption of iso are hardly known particularly
in subjects with increased risk for non-communicable
diseases.
The objectives of the present study were therefore: (a) to
investigate the actual availability, i.e. digestibility and absorp-
tion of iso from human small intestine after consumption of
iso-rich meals; (b) to examine glucose and insulin response
to iso intake in healthy subjects; (c) to study possible health
effects of a regular consumption of iso in volunteers with
hyperlipidaemia.
Subjects and methods
A total of three human intervention trials were performed. The
small intestinal digestion and absorption of iso incorporated
in different foods were examined in a sequential, not blinded
trial in healthy ileostomates. Trials 2 and 3 were performed in
a double-blind, randomised, controlled cross-over design.
Blood glucose and insulin proﬁles were determined over 3h
after the intake of iso in healthy subjects. Trial 3 investigated
the effects of regular consumption of iso in overweight
hyperlipidaemic subjects.
Trial 1 – ileostomy study on the digestion and absorption of
isomaltulose
Ten healthy subjects with an end ileostomy without ileal
resection participated in the trial (eight women and two
men; mean age of 47 years, range 33–67 years). They had
undergone colectomy between 1 and 28 years (mean 10
years) before the study; the underlying conditions were
Crohn’s disease (n 6), ulcerative colitis (n 3) or familial
adenomatous polyposis (n 1).
On two separate days, the participants consumed a test meal
including 50g iso for breakfast after overnight fasting. The
two study days were separated by at least 6d. All the test
meal products were prepared and supplied by Suedzucker
AG (Mannheim/Ochsenfurt, Germany). Test meal 1 was a
beverage (500ml); meal 2 consisted of a beverage (250ml)
and biscuits (140g) each containing 25g iso. The 140g
biscuits provided 2·3MJ, 79·2g carbohydrate, 9·8g protein,
44·8g fat. Both the test meals were consumed within
5–7min. After 5h, the subjects were served a standardised
lunch (400g lasagne: 2·8MJ, 56g carbohydrate, 24g protein,
40g fat). The ileostomy bags were collected immediately
before and hourly within the next 8h after the test meal
intake. The ileostomy efﬂuents were weighed, homogenised,
and aliquots were frozen at 2208C until analysis. To avoid
bacterial degradation of the efﬂuent, antibiotic solutions
(5ml ampicillin and 5ml metronidazole) were added to each
new applied bag. The suitability was conﬁrmed in pre-tests
with spiked ileostomy samples.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures
involving human subjects were approved by the local
Ethics Committee of the Faculty of Medicine, University of
Wu ¨rzburg, Germany. Written informed consent was obtained
from all the subjects.
Trial 1 was carried out at University of Wu ¨rzburg,
Department of Medicine II, Division of Gastroenterology,
Grombu ¨hlstr. 12, D-97080 Wu ¨rzburg, Germany.
Analytic procedures. Ileostomy ﬂuid homogenate samples
were analysed for iso, as well as glucose and fructose as
hydrolysis products using GC (Agilent 6890) and a capillary
fused silica column CP-Sil 8CB (15m £ 150mm £ 0·15mm)
with FID. Carrier gas was helium. The temperature program
was 808C for 1min, 308C/min to 1708C, 108C/min to 3508C
(3min). The method was validated beforehand. Linearity
of the GC method was conﬁrmed by analysis of standard
solutionsofdifferentisoconcentrationswitha(linear)coefﬁcient
of correlation of 0·99993. In ileostomy samples free of any
additions, iso co-eluted only with negligible amounts
(,0·1%) of unknown compounds. Repeatability was calcu-
lated from ten replicate determinations of a sample (in each
case completely separate sample preparation) with a coefﬁ-
cient of variation of 2·4% for the iso content and 0·06% for
the retention time was obtained. Recovery determined by
samples spiked at three concentration levels (10, 1 and
0·1% iso) was 96, 100 and 111%.
Sample preparation and derivatisation was carried out as
follows. Approximately, 1g of sample and 0·05g Phenyl-
b-D-glucopyranoside (internal standard) were weighed with
an accuracy of ^0·1mg. After addition of 1ml ultra-pure
water and 7·95ml pyridine, sample was stirred for 30min.
To 0·2ml of this sample, 0·8ml oxime reagent (10g hydroxyl
ammonium hydrochloride in 90ml pyridine) was added and
warmed for 30min to 608C. After cooling to room tempera-
ture, 0·4ml pyridine and 0·5ml N-methyl-N-trimethylsilyltri-
ﬂuoracetamide (MSTFA) were added to 0·1ml of this solution.
After warming to 608C for another 30min and cooling down,
the sample was directly injected into the GC. Concentrations
of saccharides were calculated based on peak area ratios of the
sample compared to standard chromatograms.
Calculations. The apparent digestibility of iso was calcu-
lated as intake of iso (50g) minus excretion of iso (g/8h) as a
percentage of intake. Furthermore, the absorption was calcu-
lated as intake of carbohydrate amount (50g iso) minus
excretion of carbohydrate amount (g/8h; sum of iso and of
glucose and fructose as resulting monosaccharides from the
intestinal hydrolysis of iso) as a percentage of intake.
Trial 2 – blood glucose and insulin response study
A total of ten healthy subjects (nine female, one male, age:
30·9 (SD 8·5)years; BMI: 23·3 (SD 2·8)kg/m
2) were studied
on two study days with respect to their blood glucose and
insulin response over 3h following ingestion of either 50g
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nof iso (Palatinosee) or suc dissolved in 0·5litre water. Sub-
jects came to the institute having fasted and refrained from
smoking for 12h. To obtain baseline values, capillary blood
glucose was measured (from the ﬁngertip), and venous
blood for insulin determination was taken via indwelling
cannula inserted in a suitable forearm vein. Thereafter, the
subjects received one portion of the iso or suc drink that
was at room temperature and was ingested within 5min.
Measurements of postprandial capillary blood glucose
concentrations and blood sampling for determination of insu-
lin in plasma were performed over 3h at 15, 30, 45, 60, 90,
120, 150 and 180min after ingestion of the test food.
Capillary blood glucose measurements were performed
using a Super GL analyzer (Hitado, Delecke-Mo ¨hnesee,
Germany), utilising the glucose oxidase technique. Measure-
ments were performed on the whole blood haemolysate in a
ﬂow chamber using membrane-bound glucose oxidase. Insulin
was analysed using an electrochemiluminescence immuno-
assay (Elecsys
w 1010/2010/MODULAR ANALYTICS E170,
Roche Diagnostics GmbH, Mannheim, Germany).
For each test food and individual subject, incremental area
under the curves above baseline of blood glucose and plasma
insulin concentrations was calculated.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures
involving human subjects were approved by the local Ethics
Committee of the A ¨rztekammer Nordrhein, Du ¨sseldorf,
Germany. Written informed consent was obtained from all
the subjects.
Trial 2 was carried out at the Proﬁl Institut fu ¨r Stoffwech-
selforschung GmbH, Hellersbergstr. 9, D-41460 Neuss,
Germany.
Trial 3 – effects of regular consumption of isomaltulose in
hyperlipidaemic subjects
Seventy-four volunteers were screened to recruit twenty sub-
jects fulﬁlling all inclusion and none of exclusion criteria.
All twenty volunteers recruited for the trial completed
the study (twelve women and eight men). Before entry,
the subjects were screened for their blood lipid status and
were considered hyperlipidaemic with baseline cholesterol
level . 6·5mmol/l and/or TAG level . 2·3mmol/l, i.e.,
levels usually associated with a higher risk for CVD
(15).
Exclusion criteria were: age , 18 years; BMI , 25
or . 40kg/m
2; history of severe chronic medical disease,
including gastrointestinal diseases and diabetes; glucocorti-
coid therapy; pregnancy; unusual dietary habits.
The study was designed as a randomised, double-blind, con-
trolled, cross-over trial with two 4-week test periods separated
by a 4-week washout phase. During the two 4-week study
periods, the participants consumed a controlled diet. The
diets were isoenergetic and composed as a typical Western
diet (low-ﬁbre and high-fat), containing the same basic
foods and test products, except that the test products provided
either 50g/d iso or 50g/d suc. Comprising 50g/d iso or suc,
the diets ﬁnally provided 47% of energy as carbohydrates,
39% of energy as fat, 14% of energy as protein and
1·4g/MJ dietary ﬁbre (Table 1). Iso and suc were included
in sweet foods (pudding, biscuits, toffees) and beverages
(milk drinks, soft drinks, tea beverages). All the test
products were prepared and supplied by Suedzucker AG.
As shown in Table 2, a 7d rotating menu including ready-
to-eat foods (Eismann Tiefku ¨hl-Heimservice, Mettmann,
Germany; Hofmann Menu ¨-Manufaktur, Boxberg-Schweigern,
Germany) was used. Meals were weighed and packaged in
the metabolic unit of the clinic. All meals were given to the
subjects to be eaten at home. Additional food was not allowed,
the participants were instructed to completely consume
the provided portions. Water, tea and coffee were allowed
ad libitum. Alcohol consumption was restricted to 500ml
beer or 250ml wine per week. The macronutrient composition
of the diet was calculated with PRODI expert 4.5 software
(Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart,
Germany). Food was given to the subjects every other day
in the metabolic unit by a study nutritionist. This regular
contact was maintained to ensure volunteers’ compliance.
In addition, the subjects were advised to return all blank
packages of the test food at the following visit. Body weight
was measured at entry and then at 2d intervals in the ﬁrst
week and thereafter at weekly intervals in both phases.
The subjects kept a daily record of subjective gastro-
intestinal parameters, stool frequency and stool consistency
during the two 4-week study periods. Abdominal distension,
ﬂatulence, abdominal pain and nausea were scored on
semi-quantitative scales from 0 (absent) to 3 (severe). Stool
consistency was also scored from 1 (hard) to 4 (watery).
Twenty-four-hour urine collections were obtained before
and after each test period and analysed for electrolytes and
albumin. At the same time venous blood was taken in the
morning after 12h overnight fasting period and analysed for
general safety measurements as well as metabolic and risk
measurements. Routine biochemical measurements and
blood lipid status were analysed in the Central Laboratory
of the University Hospital. In addition, tests for the assessment
of renal and liver function, blood glucose, HbA1c, C-reactive
protein, uric acid, electrolytes, blood coagulation tests and a
complete blood cell count were performed. Serum and
plasma samples for the determination of fructosamine, proin-
sulin, insulin, C-peptide, adiponectin, leptin, NEFA, oxidised
LDL were stored at 2808C until further analysis.
The study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures invol-
ving human subjects were approved by the local Ethics Com-
mittee of the Faculty of Medicine, University of Wu ¨rzburg,
Germany. Written informed consent was obtained from all
the subjects.
Table 1. Cross-over study: composition of the study diet
Women (n 12) Men (n 8)
Mean SD Mean SD
Metabolisable energy (MJ) 9·2 0·3 11·6 0·2
Carbohydrate (% of energy) 47·3 1·8 47·1 1·6
Protein (% of energy) 14·0 0·6 14·4 1·1
Fat (% of energy) 38·9 1·7 38·1 1·6
Dietary ﬁbre (g/MJ) 1·4 0·3 1·4 0·3
The energy, macronutrient and dietary ﬁbre intake were calculated with PRODI
expert 4.5 software (Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart,
Germany). In case of ready-to-eat foods (Eismann Tiefku ¨hl-Heimservice, Mett-
mann, Germany; Hofmann Menu ¨-Manufaktur, Boxberg-Schweigern, Germany),
the data were based on manufacturer information.
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nTable 2. Cross-over study: 7d rotating menu containing basic diet and test products for men
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Breakfast 145g bun
20g butter
20g cream cheese
25g vegetable paste
200ml drink*
145g bun
20g butter
30g soft cheese
200ml drink*
145g bun
20g butter
20g cream cheese
45g ham
200ml drink*
145g bun
20g butter
30g meat paste
200ml drink*
145g bun
20g butter
40g cheese
200ml drink*
90g bun
80g croissants†
20g butter
20g cream cheese
25g vegetable paste
200ml drink*
90g bun
80g croissants†
20g butter
30g meat paste
200ml drink*
Snack One kiwi One apple 150g fruit yoghurt One kiwi One apple One banana 100g pudding*
Lunch Ready-to-eat menu‡
125ml drink*
100g pudding*
400g lasagne†
150g fruit yoghurt
250ml drink*
Ready-to-eat menu‡
125ml drink*
100g pudding*
Ready-to-eat menu‡
150g fruit yoghurt
250ml drink*
Ready-to-eat menu‡
125ml drink*
100g pudding*
Ready-to-eat menu‡
125ml drink*
100g pudding*
Ready-to-eat menu‡
250ml drink*
Snack 55g biscuits* 20g soft drops*
200ml milk
30g cornﬂakes
55g biscuits* 20g fudges*
200ml milk
55g biscuits*
200ml milk
20g soft drops* 150g fruit curd
One apple
Dinner 250g salami baguette†
60g sausage
One tomato
180g brown bread
20g margarine
40g cheese
60g meatball†
100g cuke
300g quiche†
One tomato
Baked camembert†
90g brown bread
100g curd
200ml orange juice
135g brown bread
20g margarine
25g vegetable paste
80g meatball†
Filled ﬂaky pastry†
One tomato
150g fruit yoghurt
165g salami pizza†
150g fruit yoghurt
The calculated daily energy was 11·6MJ for men. The menu for women was lower in energy (9·2MJ) but containing the same foods.
Each ready-to-eat menu contained meat and side dishes. Total weight was 480–600g.
*Drink/food containing isomaltulose or sucrose.
†Ready-to eat food by Eismann Tiefku ¨hl-Heimservice, Mettmann, Germany.
‡Ready-to-eat food by Hofmann Menu ¨-Manufaktur, Boxberg-Schweigern, Germany.
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British Journal of NutritionTrial 3 was carried out at University of Wu ¨rzburg,
Department of Medicine II, Division of Gastroenterology,
Grombu ¨hlstr. 12, D-97080 Wu ¨rzburg, Germany.
Mean transit time and stool weight. Mean transit time was
measured from days 21–23 of each study period using the
single stool method of Cummings & Wiggins
(16) and radiopa-
que markers (P & A Mauch, Mu ¨nchenstein, Switzerland) as
described previously by Gostner et al.
(17). From days 24–26
of each study period, stools were collected for quantitative
assessment. Each stool was collected separately, frozen and
stored at 2258C. After completion of the study, stool samples
were thawed, and stool wet weight and faecal pH value were
recorded. Three-day stool collections were pooled using a
grinder. Faecal dry weight was measured after lyophilisation
(Gamma IA apparatus; Christ, Osterode, Germany) of an
aliquot to a constant weight.
Biochemical analyses. Cholesterol, TAG, HDL cholesterol
and LDL cholesterol in serum were analysed using colorimetric
enzyme kits (Roche Diagnostics). apo A1 and apo B100 were
measured immuno-turbidimetrically (Roche Diagnostics).
HbA1c measurement was performed by HPLC, and fructosa-
mine was determined using an enzymatic colorimetric assay
kit (Boehringer, Mannheim, Germany). Venous blood glucose
samples were analysed by hexokinase method (Roche Diagnos-
tics). Proinsulin concentration was determined using a RIA kit
(Linco Research, St Charles, MO, USA). Serum insulin and
C-peptide were measured by RIA (Schering GmbH, Berlin,
Germany). The homeostasis model assessment for insulin
resistance (HOMA-IR) was determined for each individual
according to Matthews et al.
(18). Oxidised LDL was deter-
mined in plasma samples using an ELISA kit (Mercodia,
Uppsala, Sweden). NEFA level was determined by enzymatic
colorimetric assay kit (Wako Chemicals GmbH, Neuss,
Germany). Adiponectin concentration was measured using a
RIA kit (Linco Research). Leptin was analysed in serum
probes with a RIA kit (Mediagnost, Reutlingen, Germany).
Statistical analysis
Statistical analyses were carried out using SPSS for Windows
version 14.0.1. Values are given as mean values and standard
deviations. The non-parametric Wilcoxon rank sum test for
paired data was used to determine the speciﬁc differences
between iso and suc (trials 2 and 3) and between the two test
meals (trial 1). Differences were considered to be signiﬁcant
at P,0·05.
In addition, for blood lipids, measurements of carbohydrate
metabolism, adipocytokines and risk factors (trial 3),
Wilcoxon test was performed to test for signiﬁcant differences
between baseline and 4-week measurements within each
treatment.
Results
Trial 1 – ileostomy study
The amount of iso excreted after intake of both the test meals
was very low, corresponding to 4·5% (test meal 1) and 1·2%
(test meal 2) of intake, indicating a high apparent digestibility
and absorption, unaffected by the nature of the meal (liquid v.
solid). After consumption of 500ml beverage including 50g
iso (meal 1), the determined apparent digestibility was
95·5%, ranging from 75·6 to 100% (median: 99·1%). The
apparent absorption rate of ingested iso from test meal 1
was estimated to be 93·6% (range: 69·3–99·8%; median:
98·1%). Similar results were found after consumption of a
combination of 250ml beverage and 140g biscuits including
50g iso. The determined apparent digestibility was 98·8%
(range: 95·3–100%; median: 99·5%) and apparent absorption
was 96·1% (range: 88·6–99·6%; median: 97·7%). Digestibil-
ity and absorption of iso were almost complete in both the
tests. Thus, in this assay, the nature of the meal (liquid or
solid) did not signiﬁcantly inﬂuence the digestibility and
absorption of iso. Data are shown in Fig. 1.
Trial 2 – blood glucose and insulin response study
The mean 3h blood glucose and insulin response curves for
the 50g portions of suc and iso are shown in Fig. 2. Iso pro-
duced the lowest blood glucose response curve (incremental
area under the curves: 118 (SD 54) v. 184 (SD 70)min £
mmol/l; P¼0·037), increasing gradually and only moderately.
A plateau rather than a peak was obtained of about 5·8mmol/l
approximately 15–30min later than the peak with suc. After
the maximum, blood glucose slowly declined and remained
above baseline until the end of testing. After intersection of
blood glucose proﬁles of suc and iso at about 60–90min,
blood glucose with iso remained higher for more than 90min.
The insulin response for the saccharides was directly pro-
portional to their glycaemic response, both in the magnitude
and shape of the response curve (incremental area under the
curves: 15208 (SD 8639) v. 23347 (SD 14451)min £ pmol/l;
P¼0·005). Iso evoked the lowest insulin response with a
maximum of 227·8pmol/l, which is more than 50% lower
compared with suc (470·1pmol/l).
Trial 3 – effects of regular consumption of isomaltulose in
hyperlipidaemic subjects
Subjects and compliance. Twenty volunteers, aged 21–61
years (mean 48·2 years) completed the study (twelve women
0
20
40
60
80
100
120
12
Test meals
%
Fig. 1. Ileostomy study: apparent digestibility, absorption and excretion of
isomaltulose from different meals.1, Test meal 1 was a beverage (500ml)
containing 50g isomaltulose; 2, test meal 2 was a beverage (250ml) and
biscuits (140g) together containing 50g isomaltulose. o, Digestibility;
, absorption; B, isomaltulose excretion.
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had the same number of subjects. The mean BMI of the
women was 31·9 (SD 3·1)kg/m
2 and of the men 33·4
(SD 2·4)kg/m
2. Mean BMI and mean body weight did not
differ between the treatments. There was a slight and similar
reduction in body weight with both the treatments (20·9
(SD 1·0)kg with iso and 21·1 (SD 0·7)kg with suc). Subjective
intestinal characteristics such as distension were usually rated
as low or unchanged and did not signiﬁcantly differ between
iso and suc. With each treatment, pain and nausea were
scored as absent. In conclusion, the daily consumption of
50g iso was well accepted and tolerated by the subjects.
The compliance of volunteers was maintained throughout
the study as also indicated by the virtually complete return
(97%) of blank packages of test products.
Routine blood measurements. Routine biochemical and
standard clinical measurements for the assessment of renal and
liver function, clotting (prothrombin time and partial thrombo-
plastin time) and blood cell counts were not signiﬁcantly differ-
ent between both the treatments. The values remained in the
normal range with both interventions (data not shown).
Urine and stool measurements. Routine urine measure-
ments, including Ca, K, Na, phosphate and albumin excretion
were comparable with both the treatments and remained in the
normal range (data not shown).
Mean values of stool frequency and stool consistency were
not signiﬁcantly different between iso and suc intervention
(data not shown). Furthermore, mean transit time (iso 47·3
(SD 13·4); suc 42·8 (SD 11·8)h) as well as wet weight (iso
151·1 (SD 55·8); suc 162·7 (SD 70·5)g/d), dry weight (iso
29·4 (SD 13·3); suc 32·2 (SD 14·8)g/d), faecal water content
(iso 121·7 (SD 51·7); suc 130·6 (SD 59·8)g/d) and pH (iso
7·3 (SD 0·3); suc 7·5 (SD 0·4)g/d) were not inﬂuenced by iso
intake and did not differ signiﬁcantly between the treatments.
Blood lipids. No signiﬁcant treatment difference was
obtained for total cholesterol (baseline: iso 6·2 (SD 1·0) v.
suc 6·2 (SD 1·0)mmol/l; week 4: iso 6·1 (SD 0·9) v. suc 6·2
(SD 0·9)mmol/l), HDL cholesterol (1·3 (SD 0·4) v. 1·3 (SD
0·4)mmol/l; 1·3 (SD 0·4) v. 1·4 (SD 0·3)mmol/l), LDL choles-
terol (3·9 (SD 1·0) v. 3·8 (SD 0·9)mmol/l; 3·8 (SD 0·9) v. 3·8
(SD 1·0)mmol/l), TAG (2·2 (SD 1·2) v. 2·5 (SD 1·9)mmol/l;
2·4 (SD 1·4) v. 2·3 (SD 1·6)mmol/l), apo A1 and apo B100 as
well as LDL/HDL ratio and Apo B100/Apo A1 ratio.
Measurements of carbohydrate metabolism. The mean
fasting levels of blood glucose, insulin, C-peptide, proinsulin,
HbA1c, fructosamine and insulin resistance (HOMA-IR) at
baseline were not signiﬁcantly different, except values of
blood glucose. Mean fasting levels at all time points were
similar in the higher normal range or in the case of proinsulin
slightly higher. There was no signiﬁcant treatment difference.
With both the interventions, there was a slight but statistically
signiﬁcant decrease in concentrations of C-peptide (base-
line: iso 1·1 (SD 0·4) v. suc 1·1 (SD 0·4)nmol/l; week4: iso
1·0 (SD 0·4) v. suc 1·0 (SD 0·3)nmol/l) and proinsulin
(17·2 (SD 11·4) v. 18·6 (SD 12·3)pmol/l; 15·1 (SD 12·8) v.
14·6 (SD 10·0)pmol/l). Signiﬁcant lower fasting blood glucose
levels (5·3 (SD 0·5) v. 5·0 (SD 0·6)mmol/l; 4·9 (SD 0·4) v. 4·9
(SD 0·3)mmol/l; P¼0·002) together with reduced HOMA-IR
(4·6 (SD 2·7) v. 4·8 (SD 2·6); 3·8 (SD 2·1) v. 3·9 (SD 1·7);
P¼0·036) were noted after the 4-week iso intervention
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Fig. 2. Blood glucose and insulin response study. (a) Blood glucose proﬁles
of 50g isomaltulose ( ) and sucrose (X) over 3h. (b) Insulin proﬁles of
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Fig. 3. Cross-over study. (a) Fasting blood glucose levels of twenty hyperlipi-
daemic subjects following consumption of either 50g isomaltulose/d or 50g
sucrose/d for 4 weeks. (b) HOMA insulin resistance of twenty hyperlipidae-
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sucrose/d for 4 weeks. Mean values were signiﬁcantly different: *P,0·05,
**P,0·01 by Wilcoxon test for paired data.
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differences in fasting blood glucose levels and HOMA-IR
were observed at 4 weeks between iso and suc.
Adipocytokines and risk factors. Adiponectin levels
were comparable with both the treatments. There was a
slight and comparable reduction in leptin concentrations
with iso and suc intervention. The cardiovascular risk factors
oxidised LDL and NEFA were stable with iso consumption
and did not differ signiﬁcantly in comparison with suc
(data not shown).
Discussion
To our knowledge, this is the ﬁrst study investigating the
digestibility and absorption of iso in vivo in human subjects.
The ileostomy model applied here is a suitable method for
evaluating absorption processes and was extensively used in
many studies for determination of small intestinal digestion
of carbohydrates
(19–24). Results from our ileostomy study
with iso conﬁrmed ﬁndings from earlier in vitro and animal
studies
(7) that iso is virtually completely digested and
absorbed from the human small intestine, irrespective of the
food matrix and the food consistency. Together, with the ﬁnd-
ings from the postprandial blood glucose and insulin determi-
nation after iso consumption, these results conﬁrm that iso is
completely, but very slowly hydrolysed and absorbed in
the small intestine, leading to a prolonged delivery of blood
glucose for metabolism. Thus, the present study conﬁrms
that iso is a completely available low glycaemic and low
insulinaemic carbohydrate.
In the 4-week cross-over trial on the effects of regular iso
consumption, iso was given within a controlled and typical
Western diet (low-ﬁbre and high-fat) in the form of a variety
of foods like pudding, biscuits, toffees and beverages
(Table 2). Iso and its products used in the present study
were well accepted and 50g/d over the 4-week test period
was well tolerated by the participants.
The 4-week cross-over study was aimed to examine the
effects of regular iso consumption instead of higher glycaemic
ingredients in hyperlipidaemic subjects. To our knowledge,
this is the ﬁrst human intervention study looking at regular
consumption of iso over a longer period. In the present
study, blood lipids (cholesterol, LDL, HDL, TAG and
apo) were not affected by low glycaemic carbohydrate iso.
Oxidised LDL and NEFA levels stayed constant both with
suc and iso. Relationships between dietary GI and blood
lipid fractions have been assessed in several prospective
observational studies. An inverse association between HDL
cholesterol and dietary GI was found in many studies
(25–27),
although one study detected no association
(28). Furthermore,
observational studies showed that TAG levels tend to rise
when GI or glycaemic load (GL) of the habitual diet increases.
However, results from the intervention trials differed
from those of observational studies. Opperman et al.
(29)
have carried out a meta-analysis of fourteen randomised, con-
trolled clinical trials to determine if low GI diets, compared
with conventional or high GI diets, have beneﬁcial effects
on markers for lipid metabolism. In the studies reviewed,
low GI diets caused a statistically signiﬁcant improvement
in total cholesterol concentrations but not in TAG, HDL and
LDL cholesterol. Another meta-analysis by Livesey et al.
(4)
demonstrated no clear evidence for a difference in TAG
following lower GI/GL intervention, although TAG levels
were reduced in those groups with the highest levels. In hyper-
lipidaemic subjects without diabetes, Jenkins et al.
(30) showed
that 4 weeks on low GI diet could reduce total cholesterol
and LDL cholesterol by about 10% and TAG by 20%
compared with high GI diet. This indicates that inﬂuence of
the overall dietary GI or GL on markers of lipid metabolism
varies between studies. Moreover, it would be conceivable
that more pronounced favourable effects of lower GI/GL
intervention may particularly present in more symptomatic
hyperlipidaemics.
With regard to carbohydrate metabolism, signiﬁcant lower
fasting blood glucose levels and insulin resistance (HOMA-
IR) were noted after 4-week iso compared with baseline,
whereas these differences were non-signiﬁcant with suc treat-
ment. However, there were no signiﬁcant differences between
iso and suc at 4 weeks in any measurement of carbohydrate
metabolism. Both the interventions slightly improved proinsu-
lin and C-peptide levels. Most intervention trials looking at
effects of GI/GL on carbohydrate metabolism were carried
out in type 2 or type 1 diabetics. Meta-analyses demonstrated
that studies in patients with type 2 diabetes showed beneﬁcial
effects of low GI/GL diets reﬂected in decreased HbA1c, fruc-
tosamine
(29,31) as well as HOMA-IR, fasting blood glucose
and insulin levels
(4). Data for subjects with unimpaired carbo-
hydrate metabolism, however, are rare. Brand-Miller et al.
(31)
reported a non-signiﬁcant decrease in fructosamine in healthy
subjects by low GI diets. In addition, Livesey et al.
(4) observed
that for improvement in fasting blood glucose levels and
glycated proteins, there is evidence that the effects are greatest
among those with poorest glycaemic control. For reduction in
fasting blood glucose, the threshold is about 5mmol/l. With
reference to insulin levels, no treatment effects were deter-
mined for concentrations , 100pmol/l
(4). Hence, our data are
consistent with the literature. In subjects with more obvious
disturbances in blood glucose control, such as people with
impaired glucose tolerance or manifest diabetes, presumably
morepronouncedbeneﬁciallongertermeffectsmaybepossible
as cause of the lower and prolonged glycaemic response and
the lower insulinaemic burden associated with iso.
In conclusion, the present study conﬁrms that iso is comple-
tely, but very slowly hydrolysed and absorbed from the human
small intestine, irrespective of food matrix and consistency,
leading to a prolonged delivery of blood glucose. Furthermore,
the present study conﬁrms that regular consumption of iso
over longer terms is well tolerated also in subjects with
increased risk for vascular diseases.
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